Call for Abstract
27th World Congress on Pharmacovigilance and Clinical Trials, will be organized around the theme “Impact of COVID-19 on Pharmaceutical Sciences & Clinical Trials ”
Clinical Trials 2020 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Clinical Trials 2020
Submit your abstract to any of the mentioned tracks.
Register now for the conference by choosing an appropriate package suitable to you.
Pharmacovigilance and Clinical Trials
Pharmacovigilance and Clinical Trials will have the rapid development of new drug and innovative therapeutics, new Pharmacovigilance procedures and methods have to be implemented for reassurance and Patient Benefit Safety Management in Pharma, Biotech and Health Care. Clinical Trails comprise the best quality level to assess the viability and wellbeing of new medications. However, in light of the fact that they are led in homogeneous conditions a long way from this present reality of solution and use, errors in patient choice or treatment conditions may change both the viability and dangers.
- Track 1-1Clinical Trial Management
- Track 1-2Post marketing Clinical Trials
- Track 1-3Challenges in Pharmacovigilance
- Track 1-4Futuristic Scope
The piece of Good Pharmacovigilance Practice and Pharmaco-epidemiology in Risk Management is widely to manufacture the probability of productive effects of a drug in a people than the probability of hostile effects and to keep up the Good Reporting Practices by avoiding the important issues in peril organization. Moreover, it is basic to center around Signal examination by party the facts on new or cloud solution impacts that is possibly caused by a medicine and that finally should provoke ensuring prosperity. The pharmacovigilance and clinical preliminaries organizations giving associations should have the Pharmacovigilance validation.
- Track 2-1Good Pharmacovigilance Practice Methods
- Track 2-2Good reporting practices
- Track 2-3Pharmacovigilance plan development
- Track 3-1Persons involved in clinical trials
- Track 3-2Medical trials in Pharmacovigilances
- Track 3-3Aim of developing Pharmacovigilance
- Track 3-4Clinical trials in Medications
- Track 4-1Medical reactions of Drugs
- Track 4-2Causes of ADR
- Track 4-3Severity of Drug Reactions
- Track 4-4Drug therapy problems
- Track 5-1Synthetic compounds
- Track 5-2Risk-benefit decisions regarding medicines
- Track 6-1Clinical Preliminaries
- Track 6-2Pharmalogical movement
- Track 6-3Translational Medicine
- Track 6-4Discovering New Medicines
- Track 6-5Preclinical Safety
- Track 7-1Clinical Research venture
- Track 7-2Treatment of subjects
- Track 7-3Statistical considerations and organization of a clinical trial
- Track 7-4Ensures the safety of the trial subjects and integrity of the data collected
- Track 8-1Drug Reaction Reports
- Track 8-2The Role of Statistics in Clinical Trials
- Track 8-3The Purpose and Fundamentals of Statistics in Clinical Trials
Track 9: Global Clinical Trials
Clinical research by academic institutions and pharmaceutical companies has followed the overall trend of globalization and has moved inexorably towards low- and middle-income countries. This trend has raised various concerns, including whether the research being conducted is useful to public health in these countries or whether economically disadvantaged populations are being exploited for the advantage of patients in rich countries. Nevertheless, clinical trials and therefore the research and health care that accompany them can directly benefit patients, especially those that would otherwise haven't any or only little access to health care services. Clinical trials are a necessary step in drug development and are conducted throughout the planet, both in developed and in developing countries. Trials themselves are thus not intrinsically immoral, and there are a spread of reasons to conduct responsible clinical trials. Doing so, for instance, is usually the sole thanks to test drugs and vaccines for diseases that predominantly afflict people.
- Track 9-1Inter professional cooperation
- Track 9-2Monitoring the impact of any such remedial actions
- Track 9-3Drug Reaction Reports
- Track 9-4Medical product authorities
Track 10: Clinical Database Management
The field of clinical knowledge management (CDM) has manifested itself thanks to demands from each the pharmaceutical business and therefore the restrictive authorities. Because the drive to “fast-track” the event of pharmaceutical product continues to accelerate, restrictive entities have responded by requiring quality-assurance standards be met in assembling the info employed in the drug analysis method. Clinical knowledge management systems (CDMS) area unit particularly important in trials conducted across medical centres during which a colossal quantity of information is made.
- Track 10-1Pharmaceutical Things
- Track 10-2Role of clinical data management in clinical trial
- Track 10-3Data Management plan in CDM
- Track 10-4Non-Drug Therapy
Drug safety relates to the potential for adverse effects related to the administration of drugs. Efforts to establish the safely profile of drugs begin early in their development, with in vitro and in vivo toxicity testing, and continue through clinical trials leading up to drug approval and following approval in specific post-marketing studies or general pharmacovigilance efforts. Pharmacovigilance (PV or PhV), also known as drug safety,is the pharmacological science relating to the collection, detection, assessment, monitoring, and prevention of adverse effects with pharmaceutical products.The etymological roots for the word "pharmacovigilance" are: pharmakon (Greek for drug) and vigilare (Latin for to keep watch). As such, pharmacovigilance heavily focuses on adverse drug reactions, or ADRs, which are defined as any response to a drug which is noxious and unintended, including lack of efficacy (the condition that this definition only applies with the doses normally used for the prophylaxis, diagnosis or therapy of disease, or for the modification of physiological disorder function was excluded with the latest amendment of the applicable legislation). Medication errors such as overdose, and misuse and abuse of a drug as well as drug exposure during pregnancy and breastfeeding, are also of interest, even without an adverse event, because they may result in an adverse drug reaction Signal Detection in Drug Safety
Tracks 12:Recent trends in Pharma and Technology
Every industry is changing at a more fast pace. Products and administrations are getting to be progressively commercialized. Innovation is playing a continuously greater part in inquire about and improvement, showcasing and promoting, and deals and dispersion. The pharmaceutical division is one that has felt this change in investigate and advancement over the past few years and will begin to feel it within the other divisions over the another decade. It's exceptionally likely that within the next decade, people will now not be pharmaceutical test subjects. Instead, cognitive computers will be utilized in biotechnology and genomic research. Instead of it taking months to see the impact of a specific drug on thousands of individuals, it'll take seconds to see the impact of thousands of drugs on billions of simulations of the human body's physiology. Body sensors are a new innovation that's right now still in clinical trials. These sensors can either be put on the body or interior of it. They degree different basic crucial signs. With the unused innovation and advancement, patients are picking up more control. They presently have the capacity to have more of a say when it comes to their body and their health. In this way, pharmaceutical companies will have to be starting taking patient needs, thoughts, and desires into consideration. Products will be more effective if patients are included in their creation and distribution. It's likely that over the coming a long time, numerous companies within the pharmaceutical industry will make persistent admonitory sheets. The pharmaceutical industry is changing at each an each level.
Tracks 13:Pharmacovigilance and Risk Management
Pharmacovigilance and Risk Management comprises set of pharmacovigilance activities and interventions designed to identify, characterise, prevent or minimise risks relating to medicinal and therapeutic products including the assessment of the effectiveness of their clinical interventions and combination therapies. Drug industry need to promote companies in pharmacovigilance practice to use information technology and to review softwares used in pharmacovigilance and clinical trials. Monitoring unlicensed, off labels and orphan drugs is major task in risk management. Many experts from different pharmacovigilance CRO's , pharmacovigilance service providers and industrial delegates are participating in this conference to share their knowledge and discuss about the new updates.
Tracks 14: Prevalence of Potential Drug- Drug Interaction
The objective of this study is to estimate the prevalence and describe the characteristics of pDDIs in medical prescriptions of hospitalized surgical patients. In this cross-sectional study, we analyzed 370 medical prescriptions from the surgery unit of a Mexican public teaching hospital. The identification and classification of potential drug-drug interactions were performed with the Micromedex 2.0 electronic drug information database. Results were analyzed with descriptive statistics and we estimated OR (odds ratio) to determine associated risk factors.
Pharmacovigilance main aim is to convey clear info regarding drug safety and its Risk or advantages of medicine to the patients. Patients are main finish users of medication. Patient info leaflet with reference to medication to be provided to the patient to extend the benefits of the medication and to scale back the chance related to them. It's essential for Risk decrease by creating associate early detection and preventing the progression of the adverse effects. Complete info of unintended and severe adverse events may well be finding through the Pharmacovigilance. It couldn't be done through clinical trials that are conducted in associate in vivo methodology.
- Track 15-1Inadequacies of a currently implemented risk-minimization action plan
- Track 15-2Monitoring the impact of any such remedial actions
- Track 15-3Healthcare
Tracks 16: Drug repurposing to treat Viruses: COVID-19
<p 0px="" 16:="" background-color:="" drug="" margin:="" n="" p="" repurposing="" style="\" text-align:"="" text-align:="" to="" tracks="" treat="" viruses:=""> Drug repurposing is a methodology for making more value from an existing drug by targeting diseases by focusing on infections other than that for which it was initially proposed, For instance, teicoplanin, oritavancin, dalbavancin and monensin are affirmed antibiotics that have been appeared to inhibit corona- and other viruses in the research facility. The researchers reviewed information on the discovery and development of wide-spectrum antiviral agents (BSAAs), which are drugs that target viruses from two or more different viral families. They condensed what they found for 120 drugs that had just been demonstrated to be ok for people use and made a database, which is uninhibitedly available Thirty-one of these were found by the researchers to be possible candidates for prophylaxis and treatment of the COVID-19 infections. The researchers also found that clinical investigations have recently begun of five possible drug candidates to treat the virus that causes COVID-19.
- Track 16-1Corona Virus Drugs
- Track 16-2Coronavirus vaccine by Immuno Precise Antibodies
- Track 16-3Clinical Development of Drugs
- Track 16-4Targets for Antiviral Drugs
Medical devices layout for drug delivery through the pulmonary and nasal routes. These routes are of interest for local delivery, as in asthma, but also for rapid delivery of drugs to the system circulation and direct delivery to the central nervous system. Devices that report for particular anatomical and physiological features of the intranasal and pulmonary routes will be characterized. Drug delivery devices are specialized tools for the delivery of a drug or therapeutic agent via a particular route of administration. Such devices are used as bit of one or more medical treatments. Many in the industry have lengthy felt overly laden by what they acknowledge to be an unessential complicated approval process. Critics declare it impedes innovation and detain the opportunity of better health care. In order to help innovators import health care to the public.
- Track 17-1 Medical Devices for Drug Delivery
- Track 17-2Biomedical Instrumentation Measurements
- Track 17-3Quality by Design (QBD)
- Track 17-4Ophthalmic and ENT Instruments
Tracks 18:Pharmacovigilance and Cosmetovigilance
Pharmacovigilance (PV or PhV), also known as drug safety, is the pharmacological science relating to the collection, detection, assessment, monitoring, and prevention of adverse effects with pharmaceutical product. The etymological roots for the word "pharmacovigilance" are: pharmakon (Greek for drug) and vigilare (Latin for to keep watch). As such, pharmacovigilance heavily focuses on adverse drug reactions, or ADRs, which are defined as any response to a drug which is noxious and unintended, including lack of efficacy (the condition that this definition only applies with the doses normally used for the prophylaxis, diagnosis or therapy of disease, or for the modification of physiological disorder function was excluded with the latest amendment of the applicable legislation). Medication errors such as overdose, and misuse and abuse of a drug as well as drug exposure during pregnancy and breastfeeding, are also of interest, even without an adverse event, because they may result in an adverse drug reaction.
Cosmetovigilance is the ongoing and systematic monitoring of the safety of cosmetics in terms of human health. The aim is to detect adverse effects of cosmetic products, and to prevent adverse effects by taking appropriate measures. Regulations for cosmetic products primarily address the safety of products that may be used by large populations of healthy consumers. The identification and analysis of adverse effects related to cosmetic products is a process that is currently still, to a large extent, industry driven. It is the responsibility of manufacturers to determine that products and ingredients are safe before they are marketed, and then to collect reports of adverse reactions.
Tracks 19:Pharmacokinetics and Pharmacodynamics in Drugs
Pharmacokinetics is currently defined as the study of the time course of drug absorption, distribution, metabolism, and excretion. Clinical pharmacokinetics is the application of pharmacokinetic principles to the safe and effective therapeutic management of drugs in an individual patient. Primary goals of clinical pharmacokinetics include enhancing efficacy and decreasing toxicity of a patient’s drug therapy. The development of strong correlations between drug concentrations and their pharmacologic responses has enabled clinicians to apply pharmacokinetic principles to actual patient situations.
Pharmacodynamics refers to the relationship between drug concentration at the site of action and the resulting effect, including the time course and intensity of therapeutic and adverse effects. The effect of a drug present at the site of action is determined by that drug’s binding with a receptor.
- Track 19-1Absorption of drugs
- Track 19-2Biotransformation/metabolism
- Track 19-3Pharmacodynamics
- Track 19-4Distribution of drugs
- Track 19-5Pharmacokinetic parameters
<span style="\"text-align:" justify;\"="">Tracks 20: Pharmaceutical Research and Development
For developing a new medicine it will take nearly 10-15 years and on average and costs an average of $2.6 billion. In discovery procedure comprises the initial stages of research, which are intended to recognize an investigational drug and perform primary tests in the lab. This first stage of the process takes three to six years. By the end, investigators hope to identify a capable drug aspirant to further study in the lab and in animal models, and then in people. These developments offer great ability, but also add complexity to the R&D process. In order to ensure the safety and efficacy of personalized therapies that are used along with diagnostics, clinical trial protocols must be improved and increased.
- Track 20-1Recent trends in Drug Discovery and Development
- Track 20-2Analytical strategies for pharmaceutical products
- Track 20-3Pharmacoeconomics and pharma market research
- Track 20-4Drug Prices and Consumer Value in R&D
- Track 20-5Neglected Tropical Disease Treatments
Two powerful megatrends — dramatic deceleration in U.S. market growth and significant restructuring of the healthcare system — are at play in the U.S. pharmaceuticals industry. The U.S. pharmaceutical market is the world’s most important national market. Together with Canada and Mexico, it represents the largest continental pharma market worldwide. The United States alone holds over 45 percent of the global pharmaceutical market. In 2016, this share was valued around 446 billion U.S. dollars. The biopharmaceutical companies in the United States exported goods in the amount of some 31 billion U.S. dollars during 2016. In the United States, there are an estimated 100,000 OTC drug products marketed and sold in a variety of outlets, such as pharmacies and convenience stores. TH revenue for the OTC drugs also add to the pharma market growth. Top markets for pharmaceutical products continue to be developed countries in Western Europe, East Asia, and North America with high per capita spending on healthcare, growing elderly populations, and advanced regulatory systems. Though ranked lower, there are growing opportunities in developing countries like China as incomes and healthcare spending increases. The pharmaceutical sector has consistently been one of the most R&D intensive industries in the United States. The research-based industry generally allocates around 15 to 20 percent of revenues to R&D activities and invests over $50 billion on R&D annually.
- Track 21-1Generic Drugs Market
- Track 21-2Over-the-Counter (OTC) Drugs and Dietary Supplements
- Track 21-3Onco medicine market
- Track 21-4Immunology and Oncolytic Virology
- Track 21-5Biosimilars market
- Track 21-6Antibody Drug Conjugates
With more stringent compliance parameters set by the USFDA the quality assurance of pharmaceutical products is ensured. In addition to cGMP, GLP and GCP practices as per the US Federal law pharma products should comply with 21CFR regulations. Also on a regular basis the FDA organizes compliance programs for the pharma industries in program areas like Biologics (CBER), Bioresearch Monitoring (BIMO), Devices/Radiological Health (CDRH), Drugs (CDER), Food and Cosmetics (CFSAN), Veterinary Medicine (CVM). The results of regulatory audits NAI – No Action Indication, VAI – Voluntary Actions Indicated, OAI – Official FDA Action Indicated are also critical to decid
- Track 22-1Food and Drug Administration (FDA)
- Track 22-2Medicines and Healthcare Products Regulatory Agency (MHRA
- Track 22-3Therapeutic Goods Administration (TGA)
- Track 22-4Central Drug Standard Control Organization (CDSCO)
- Track 22-5European Medicines Agency (EMEA)
International Organization for Standardization (ISO) 9000 requirements do not have the same status of “the law” in the U.S. as do requirements listed in the Code of Federal Regulations (CFR). Because 21 CFR 210 and 211 have legal status, the U.S. Justice Department has extensive powers to ensure compliance. For example, product in the marketplace can be seized, fines can be levied, and personal liability can be assigned. So, management must understand that auditing must be taken seriously, and the requirements listed are just that – requirements. While audits are the common place in the pharmaceutical industry, the preparedness for those events varies. The companies that develop a risk-based approach to audits are able to remain competitive while meeting quality and government compliance standards on a regular basis. Conversely, the companies that have not implemented strong processes are putting themselves at risk for non-compliance. According to the Federal Food, Drug and Cosmetic Act, “Registered domestic drug establishments shall be inspected by the FDA at least once every two years.” Under some conditions the inspections may be even more frequent, As regulations become more stringent, regulatory authorities are likely to step up audits which is even more reason for companies to be prepared
- Track 23-1Product traceability
- Track 23-2Laboratory operations
- Track 23-3Equipment validation
- Track 23-4Review the doâ€™s and donâ€™ts during the auditBuilding and facility maintenance
- Track 23-5Audit tools based on 21 CFR 210 & 211, ICH Q10
- Track 23-6Audits, including capacity, quality assurance and post-market quality system verification
A particle with at least one dimension less than 100nm is a nanoparticle. They are composed of synthetic or semisynthetic polymers carrying drugs or proteinaceous substances. Nanoparticles have developed as capable vehicles to deliver drugs in the body. Nanoparticles comprising encapsulated, dispersed, absorbed or conjugated drugs have exceptional characteristics that can lead to higher performance in a variety of dosage forms. Nanoparticles are one of the novel drug delivery systems which can be of potential use in controlling and targeting drug delivery as well as in cosmetic textiles and paints. There are recent developments in the use of nanoparticles as drug delivery systems to treat a wide variety of diseases.
- Track 24-1Nanocarriers and their applications
- Track 24-2Nanocarriers in cancer therapy
- Track 24-3Uses and advantages of nanoparticles in medicine
- Track 24-4Nanoparticles for drug delivery
Tracks 26:Pharmaceutical Nanotechnology: Challenges and Opportunities
Pharmaceutical nanotechnology is most innovative field in the pharmaceutical industry. Nano technology is dealing with new emerging technologies. Application of nanotechnology in imaging, diagnostics and therapeutics is considered as an important factor. The drug delivery system positively impacts the rate of absorption, distribution, metabolism, and excretion of the drug or other related chemical substances in the body. Within regulatory boundaries thermodynamics and nanotechnology are considered to be evolving tools to provide new and integrated knowledge for the production of new medicines.
Nanotechnology speaks to a stage for creating progressive changes and enhancements to a wide range of parts of pharmaceutical assembling. Pharmaceutical nanotechnology has provided fine-tuned diagnosis and focused treatment of disease at a molecular level. Nano technology is having an utmost importance in Gene therapy.
- Track 25-1Drug designing and Molecular Modelling
Tracks 27:Drug Delivery Technologies & Drug Designing and Development
The global drug delivery technology market is projected to reach USD 1,669.40 Billion by 2021 from USD 1,179.20 Billion in 2016, at a CAGR of 7.2% during the forecast period. The North American drug delivery technologies market is projected to reach USD 758.7 Billion by 2021 from USD 520.0 Billion in 2016, at a CAGR of 6.5% during the forecast period. Bringing one new drug to the public typically costs a pharmaceutical or biotechnology company on average more than $1 billion and takes an average of 10 to 15 years. Each drug undergoes a stringent process of discovery, development, approval and finally, public use.
- Track 26-1Vaccine Based Drug Delivery Technology
- Track 26-2Drug Design Software
- Track 26-3Smart Drug Delivery Systems
- Track 26-4Advances in Drug Delivery
- Track 26-5Nano Particulate Drug Delivery Systems
- Track 26-6Medicinal Chemistry in Drug Discovery
- Track 26-7Micro & Nano Technology
Health economics is a tool to help us prioritise different and sometimes competing health care interventions for these fixed resources and, in doing so, health care is treated as a commodity like any other. Knowledge of health economics coupled with political insight is essential to understand resource allocation and expenditure in a modern health care system. Pharmacists, with their unique knowledge of medicine, are crucial in using pharmacoeconomic analysis to influence expenditure and distribution of resources on medicines. Design and management of pharmacoeconomic studies
• cost and burden of illness studies,
• drug utilization,
• budget impact analysis,
• modeling and simulations
- Track 27-1ROI: Return on Investment
- Track 27-2Economic Evaluation Of Pharmaceuticals
- Track 27-3Quality-Adjusted Life Years
- Track 27-4Effectiveness Analysis
Track: 28linical Research Nursing
The term nursing research is characterized as the deliberate, target procedure of investigating marvels of significance to nursing. Utilizing this definition, nursing research incorporates all reviews concerning nursing work on, nursing instruction, and nursing organization. Additionally, thinks about concerning medical attendants themselves are incorporated into the general class of nursing examination. The term clinical nursing research exploration is utilized here to show nursing research including customers or studies that have the potential for influencing the care of customers, for example, considers with creatures or with alleged typical subjects. It likewise has an extensive concentrate on counteractive action and wellbeing advancement instead of the medicinal model.
Track: 29 Oncology Clinical Research
Oncology is a branch of prescription that arrangements with tumours. A therapeutic expert who hones oncology is an oncologist. Integrative oncology deals with the brain, body, and soul. Modalities of development, touch, nourishment, and care are utilized inside routine disease care to address and enhance indications and personal satisfaction. That is the reason numerous experts, including medicinal specialists, have grasped the quickly extending field of integrative oncology, which melds the best of customary and option medications. Immuno-oncology treatments enact our invulnerable framework, making it ready to perceive growth cells and annihilate them. Since tumor cells are altogether different from ordinary cells in the body, the resistant framework assaults them when it can remember them. Neuro-oncology assesses and treats individuals with essential and optional tumors of the cerebrum, spinal line, and the layers encompassing the mind and spinal rope (meninges). Oncologic Emergencies, as the term infers, are difficulties coming about because of a growth itself, a Para neoplastic disorder, or from treatment of malignancy that require prompt consideration and inversion, if conceivable. Inpatient treatment is an absolute necessity and frequently these conditions require intercession in an escalated mind setting.
With the expanded in clinical R&D and fund needs within the complexities of a clinical improvement, a hazard the board has become a elementary and indispensable piece to a clinical preliminary administration to ensure the nice profit for the speculation. The middle of a hazard the executives is distinctive proof and analysis of dangers 1st and foremost and it's likewise persistent reason for hazard bearing exercises in clinical preliminary. Once issuing of direction on a Risk-Based observation by FDA, the patrons/CROs have shown a definite fascination for receiving a particular thanks to alter a hazard appraisal in clinical preliminaries. Hazard appraisal is associate economical procedure for distinctive and assessing occasions that would be influence the accomplishment of the clinical examination targets.
Track: 31 Clinical Data Management
The Clinical Data Management is the system of the dealing with data from the clinical primers. The regular goal of any clinical data the board is the system is to convey and to keep up quality data. Likewise, this office is unnecessarily drawn in with the general social event and in treatment of the clinical starter data. Also, the Data Management bunches that make gadgets for collection of data at the clinical primer regions, and quality check the assembled data for missteps and raise hails if there ought to emerge an event of any mistake is perceived. They develop the instruments for the check, endorsement and the quality control of the data collected during the clinical primer. Clinical data executives to ensure the trustworthiness and the mystery of accumulated data are too much kept up at all the events.